Updated August 31, 2015 This content is archived.
A research team led by Richard M. Gronostajski, PhD, professor of biochemistry, has discovered a new way to generate oligodendrocytes, which has the potential to enhance treatments for multiple sclerosis (MS). “In terms of treatment, this could lead to the development of a small molecule that could be used to shut off NFIX activity in MS patients, thus promoting the growth of more oligodenrocytes,” said Gronostajski.